Sarepta Therapeutics (SRPT) Upgraded at BidaskClub

James Marshall
December 25, 2017

Granite Point Capital Management Lp sold 16,700 shares as Sarepta Therapeutics Inc (SRPT)'s stock rose 22.49%. The institutional investor held 150,000 shares of the health care company at the end of 2017Q3, valued at $6.80 million, down from 383,047 at the end of the previous reported quarter. Tirschwell & Loewy Inc who had been investing in Dentsply Intl for a number of months, seems to be bullish on the $15.12 billion market cap company.

In related news, CEO Douglas S. Ingram bought 38,138 shares of the company's stock in a transaction on Wednesday, November 8th. About 2.31M shares traded. It has outperformed by 80.80% the S&P500. GenTrust LLC acquired a new stake in Sarepta Therapeutics during the fourth quarter worth approximately $205,000. It also increased its holding in Tesaro Inc (NASDAQ:TSRO) by 25,000 shares in the quarter, for a total of 80,000 shares, and has risen its stake in Clovis Oncology Inc (NASDAQ:CLVS).

The stock increased 1.44% or $0.84 during the last trading session, reaching $59.36. 1,318,853 shares of the company's stock were exchanged, compared to its average volume of 1,462,705. It has outperformed by 17.82% the S&P500.

Sphera Funds Management Ltd, which manages about $700.90 million US Long portfolio, upped its stake in Portola Pharmaceuticals Inc (NASDAQ:PTLA) by 105,000 shares to 145,000 shares, valued at $7.83M in 2017Q3, according to the filing. About 423,624 shares traded.

Investors sentiment increased to 2.88 in 2017 Q3. Its up 1.36, from 1.52 in 2017Q2. It increased, as 24 investors sold Sarepta Therapeutics, Inc. shares while 27 reduced holdings.

Hedge funds have recently made changes to their positions in the business. Cambridge Investment Rech Advsrs holds 0% in Sarepta Therapeutics, Inc.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, October 25th. Voya Investment Ltd Liability Company reported 629,053 shares or 0.06% of all its holdings. California State Teachers Retirement has invested 0.01% of its portfolio in Sarepta Therapeutics, Inc. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 96.82% since December 24, 2016 and is uptrending. (NASDAQ:SRPT). Bnp Paribas Arbitrage Sa holds 6,792 shares. Sarepta Therapeutics earned a news impact score of 0.13 on Accern's scale. Hanson Mcclain Inc owns 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Intll Gru reported 39,644 shares or 0.01% of all its holdings. Moreover, Pointstate Lp has 0.15% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Eagle Asset Mngmt Inc has invested 0.29% in Sarepta Therapeutics, Inc. Sarepta Therapeutics Inc now has $3.62B valuation. On average, equities research analysts expect that Sarepta Therapeutics Inc will post ($0.94) earnings per share for the current year. (NASDAQ:SRPT) to report earnings on February, 27. Pnc Financial Services stated it has 162,921 shares. Finally, Robert W. Baird reiterated a buy rating and issued a $101.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, October 17th. Sarepta Therapeutics has $108 highest and $4 lowest target. (NASDAQ:XRAY) on Monday, September 21 to "Outperform" rating. The rating was initiated by Goldman Sachs on Tuesday, December 20 with "Neutral". The company was maintained on Tuesday, July 18 by Leerink Swann. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. The firm has "Underperform" rating given on Friday, April 29 by Jefferies. As per Wednesday, September 6, the company rating was maintained by J.P. Morgan. The rating was upgraded by RBC Capital Markets to "Outperform" on Monday, September 19. The firm has "Neutral" rating by Piper Jaffray given on Monday, January 18.

Since October 3, 2017, it had 0 insider purchases, and 1 sale for $575,000 activity. One research analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have given a buy rating to the stock.

Analysts await Sarepta Therapeutics, Inc. The stock of T-Mobile US, Inc. (NASDAQ:CRUS) earned "Buy" rating by Stifel Nicolaus on Thursday, November 2. The rating was upgraded by SunTrust on Wednesday, April 5 to "Buy". Eqis Capital Incorporated reported 0.02% in DENTSPLY SIRONA Inc. Sarepta Therapeutics has an average rating of "Buy" and an average price target of $64.14. Finally, Instinet reissued a buy rating and issued a $84.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 2nd. The company was maintained on Tuesday, October 25 by FBR Capital. Trexquant Lp owns 8,846 shares for 0.1% of their portfolio. The stock has "Buy" rating by Bernstein on Tuesday, September 1.

Investors sentiment decreased to 1.06 in 2017 Q3. Its up 0.01, from 0.82 in 2017Q2. It is positive, as 36 investors sold CRUS shares while 105 reduced holdings. 1 funds opened positions while 5 raised stakes. Regions Fincl reported 7,914 shares stake. Mutual Of America Mgmt Limited Liability Company reported 1,200 shares. Pinnacle Assocs Ltd has invested 0.28% of its portfolio in Sarepta Therapeutics, Inc. The Florida-based Dreman Value Mngmt L L C has invested 0.02% in Cirrus Logic, Inc. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. (NASDAQ:TMUS). Chevy Chase Tru holds 3,491 shares or 0% of its portfolio. Panagora Asset Management Inc invested in 121,713 shares. (NASDAQ:SRPT) or 74 shares. Boston Private Wealth Ltd Com invested in 12,310 shares or 0.03% of the stock. 6,325 are held by Bellecapital Interest Ltd. Iowa Bancorp holds 3.04% or 86,694 shares.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER